Presentation at the American Society for Microbiology NGS Conference highlights utility of PacBio’s highly accurate long-read sequencing platform in disease surveillance
MENLO PARK, Calif., December 16, 2020 — Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced initial findings from the company’s research collaboration with Labcorp that is focused on SARS-CoV-2 and the related immune response to COVID-19.
Announced in April 2020, PacBio and Labcorp are collaborating to develop a production-scale assay for sequencing the complete genome of thousands of SARS-CoV-2 viruses from de-identified positive patient samples using the PacBio Sequel® II System. Labcorp is currently using this information to shed light on viral evolution during the early pandemic, mutations arising in different geographic regions, and the implications for disease severity and outcomes.
“COVID-19 will continue to be an area of significant clinical research in the months and years to come as we work toward gaining a more detailed understanding of this complex disease and the human host’s immune response,” said Jonas Korlach, PhD, Chief Scientific Officer at PacBio. “Labcorp has demonstrated how production-scale assays, developed for the PacBio platform, can enable near real-time sequencing of samples to enhance pathogen surveillance and better inform response. We look forward to expanding our collaborations with leading clinical organizations like Labcorp that are focused on the development of new tools for monitoring, diagnosing, and treating infectious diseases.”
Utilizing PacBio’s Single Molecule, Real-Time (SMRT®) Sequencing platform, Labcorp has generated more than 6,500 high-resolution complete genomes from people infected with the SARS-CoV-2 virus who were sampled in the United States during the early phase of the pandemic (approximately March - May 2020). The viral sequencing assay developed by Labcorp makes use of 1.2 kb overlapping amplicons multiplexed at a cost-effective level of 600-1,000 patient samples per SMRT Cell.
The highly accurate long-read sequencing data generated by the Sequel II System has been integrated with additional phenotypic information collected by Labcorp to highlight the role of geography, demographics, and temporal details. As vaccines are widely implemented and immune pressure is increased, data may be useful in the surveillance of new viral mutations as they appear in the population.
Future research initiatives planned include the sequencing of some 20,000 archived samples from before March 15, 2020 which could be used to identify when and where specific genotypes entered the United States and establish a baseline for tracking viral evolution over time. Labcorp also hopes to perform follow-on sequencing of full-length HLA (Human Leukocyte Antigen) genes from the same samples to further examine immune response to COVID-19.
SMRT Sequencing technology is uniquely able to generate HiFi reads, which are both highly accurate and long. These qualities are well-suited for applications like viral sequencing, which requires the ability to distinguish variants within complex populations of closely related virions that may differ by very few single nucleotide variants across an entire viral genome or viral gene. For example, with the release of new therapeutics and the imminent release of several vaccines, scientists will want to monitor how SARS-CoV-2 continues to evolve within hosts, over time in a community, and across geographic regions.
Initial findings from this collaboration were presented by Michael Levandoski, PhD, Research Scientist, at Labcorp on December 8, 2020 during the American Society for Microbiology NGS Conference in a presentation titled, “Geographic and Temporal Mapping of the SARS-CoV-2 Pandemic in the United States.” More information can be found at: https://asm.org/Events/ASM-NGS/Scientific-Program.